May 19 (Reuters) - Horizon Pharma Plc HZNP.O
* Says anticipates a reduction to 2016 adjusted ebitda of
approximately $10 million versus prior guidance
* Also licensed u.s., european and canadian intellectual
property rights for interferon gamma-1b for treatment of
friedreich's ataxia
* Under terms of separate agreement with undisclosed third
party, co licensed u.s., european, canadian ip rights for
interferon gamma-1b
* Co will immediately begin investing in related
manufacturing, supply chain, regulatory,commercial activities
for interferon gamma-1b
* To immediately begin investing in related manufacturing,
supply chain, regulatory and commercial activities for
interferon gamma-1b
* Paid boehringer ingelheim eur5 million upon signing, will
pay eur20 million upon closing for rights for interferon
gamma-1b in territories outside u.s, canada, japan
* To Acquire Worldwide Rights To Interferon Gamma-1B from
boehringer ingelheim international gmbh
Source text for Eikon: ID:nMKWQVYY1a
Further company coverage: HZNP.O
(Bengaluru Newsroom: +1-646-223-8780)